A Lancet study finds that natural immunity against severe COVID-19 is strong and long-lasting for all variants in previously infected individuals. However, protection against Omicron BA.1 reinfection is reduced for those with past pre-Omicron infections. Researchers stress that vaccination is still
A comprehensive review and meta-analysis published in The Lancet reveals that natural immunity against severe COVID-19 is strong and long-lasting for all variants, including Omicron BA.1, in individuals previously infected. Protection against reinfection, symptomatic disease, and severe illness is at least equal to that provided by two doses of mRNA vaccines. However, past infection with pre-Omicron variants resulted in reduced natural immunity protection against reinfection with Omicron BA.1.
Past infection with pre-Omicron variants provided substantially reduced natural immunity protection against reinfection with Omicron BA.1 . “Vaccination is the safest way to acquire immunity, whereas acquiring natural immunity must be weighed against the risks of severe illness and death associated with the initial infection,” says lead author Dr. Stephen Lim from the Institute for Health Metrics and Evaluation at theAs IHME co-author Dr. Caroline Stein explains: “Vaccines continue to be important for everyone in order to protect high-risk populations such as those who are over 60 years of age and those with comorbidities.
It included 65 studies from 19 countries and evaluates the effectiveness of past infection by outcome , variant, and time since infection. Studies examining natural immunity in combination with vaccination were excluded from the analyses.Analysis of data from 21 studies reporting on time since infection from a pre-Omicron variant estimated that protection against reinfection from a pre-Omicron variant was about 85% at one month—and this fell to about 79% at 10 months.
“The weaker cross-variant immunity with the Omicron variant and its sub-lineages reflects the mutations they have that make them escape built-up immunity more easily than other variants,” says IHME co-author Dr. Hasan Nassereldine.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Study: COVID-19 Omicron Variant Is More Deadly Than the Seasonal FluDuring the 2021-2022 flu season, patients who were hospitalized with the flu had a 55% lower likelihood of dying within 30 days compared to those who were hospitalized with the COVID-19 Omicron variant. According to new research being presented at the European Congress of Clinical Microbiol
Read more »
To Test or Not: A Call to Action for Improving Alpha-1 Antitrypsin Deficiency Management❓ Do you know when to recommend testing for alpha-1 antitrypsin deficiency? Take our latest CME to test your knowledge! AATD PulmTwitter 🌐 Developed in collaboration with ClevelandClinic & AlphaFriend. 📝
Read more »
Cardano's (ADA) Game-Changing Innovation 'Aiken' Is Live in Alpha PhaseCardano's $ADA major innovation enters alpha phase, here's what 'Aiken' is about cardano cardanoada cardanocommunity iohk cardano
Read more »
Sun Bum Wants Gen Alpha Consumers to Show Off Their Artistic TalentKicking off May 15, Sun Bum contest encourages kids between the ages of 5-12 to submit illustrations depicting their ideal day with Sonny, who is Sun Bum’s ape mascot and, according to the brand’s VP of marketing, already a hit among young consumers.
Read more »
New (Itchy) COVID Symptom Reported as ‘Arcturus' Fuels NY Area SpreadThought COVID was done with the surprises? Not yet, apparently. Those itchy, red eyes you have that you assumed were just the start of allergy season? It could very well be something called “Arcturus” instead. XBB.1.16, a subvariant of the Omicron variant of the COVID-19 virus that has acquired that unusual stellar label, appears to be spreading quickly in some…
Read more »
New Assay Hailed as a Game Changer for Early Parkinson's DxAn alpha-synuclein seed amplification assay is being hailed as a game changer in the early diagnosis and characterization of PD.
Read more »